• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
KANG Zhenhua, CHEN Yuandong, XU Cheng, YOU Jian, QIN Minjian, QIN Yong. Optimization of pramipexole hydrochloride sustained-release tablets using Box-Behnken design and mechanism of in vitro drug release[J]. Journal of China Pharmaceutical University, 2015, 46(1): 66-72. DOI: 10.11665/j.issn.1000-5048.20150108
Citation: KANG Zhenhua, CHEN Yuandong, XU Cheng, YOU Jian, QIN Minjian, QIN Yong. Optimization of pramipexole hydrochloride sustained-release tablets using Box-Behnken design and mechanism of in vitro drug release[J]. Journal of China Pharmaceutical University, 2015, 46(1): 66-72. DOI: 10.11665/j.issn.1000-5048.20150108

Optimization of pramipexole hydrochloride sustained-release tablets using Box-Behnken design and mechanism of in vitro drug release

More Information
  • The formulations of pramipexole hydrochloride sustained-release tablets were screened by single factor test and optimized by Box-Behnken design. The effects of the viscosity and content of hydroxypropyl methyl cellulose, as well as the insoluble sustained-release material combined with HPMC K100M on the in vitro release behavior were investigated. After single factor screening, a three-factor, three-level Box-Behnken design was used for optimization using the contents of HPMC K100, Eudragit RSPO and Eudragit L100 as independent variables, and the cumulative release at different time as responses. The optimal range of the three-factor optimized by Box-Behnken design, one of the optimized formulations was achieved with HPMC K100M of 101. 5 mg, Eudragit RSPO of 98 mg, and Eudragit L100 of 13. 7 mg, and the observed responses of the optimized formulation were very close to the predicted values. The in vitro drug release mechanism of the tablet was studied by drug released model fitted with different equations. The results explained that Eudragit RSPO promoted the release of the pramipexole hydrochloride, while Eudragit L100 blocked the release, and there was an antagonism between them. In conclusion, the drug release behavior of optimized formulations prepared by Eudragit RSPO/L100 was stable, less pH-dependent, which improved the drug bioavailability in vivo.
  • [1]
    Wang XN,Liu GD,Xiao Q,et al.Observation of curative effect of dopamine receptor antagonist pramipexole for treatment on non-motor symptoms of Parkinson′s disease[J].J Clin Neur(临床神经病学杂志),2010,23(4):299-301.
    [2]
    Chwieduk CM,Curran MP.Pramipexole extended release[J].CNS drugs,2010,24(4):327-336.
    [3]
    Thomas F.Preparation and use of pramipexole hydrochloride sustained-release tablets:CN,101005830B[P].2010-09-29[2014-06-09] .
    [4]
    Wang XD,Liu K,LiQ K,et al.Optimized formulation of levofloxacin gastric floating tablet by Box-Behnken design[J].Chin J Mod Appl Pharm(中国现代应用药学),2013,30(4):406-411.
    [5]
    Deepan T,Paulambethkar K,Vijayalakshmi R,et al.A validated RP-HPLC method for the estimation of pramipexole dihydrochloride in pH armaceutical dosage form[J].World J Chem,2012,7(2):59-63.
    [6]
    Sekhar KS,Nagabhushanam MV,Rao KRSS,et al.Formulation development and in vivo evaluation of pramipexole dihydrochloride monohydrate extended release tablets for Parkinson′s disease[J].Der Pharm Lett J,2013,5(4):153-163.

Catalog

    Article views (1621) PDF downloads (2188) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return